India green lights clinical trials of Akston Biosciences’ second-generation vaccine

India -India kicks off clinical trials for the second generation Covid-19 vaccine of the US-based Akston Biosciences. The US firm has announced that the first 100 subjects were done in an open-label in India. The open-label study or AKS-452 is based on the protein subunits of the Covid-19 candidate. The doses are shelf-safe for at least six months at room temperature and are able to maintain potency for one month. It will be a big step for India to be able to procure a good deal with the firm as the drug controller of India has given nod for theIndia -India kicks off clinical trials for the second generation Covid-19 vaccine of the US-based Akston Biosciences. The US firm has announced that the first 100 subjects were done in an open-label in India. The open-label study or AKS-452 is based on the protein subunits of the Covid-19 candidate. The doses are shelf-safe for at least six months at room temperature and are able to maintain potency for one month. It will be a big step for India to be able to procure a good deal with the firm as the drug controller of India has given nod for the […]